Uveitis is one of the leading causes of blindness globally. It has a diverse etiology and is a challenging ocular disease to treat. The mainstay of treatment is corticosteroids, but the serious side effects associated with its long-term use have left a huge clinical unmet need for many years. 

Immunosuppressive agents and biologics are gaining momentum as treatments for uveitis, and the treatment landscape for patients with severe forms of uveitis has evolved appreciably in recent years, thanks to the approval of Humira for non-infectious posterior segment uveitis. Novel non-corticosteroid molecules and new drug delivery routes appear in the late-stage uveitis pipeline, generating further hope for the evolution of the treatment landscape. A low level of awareness and low affordability and healthcare access, particularly in India and China, limit the overall market size for uveitis in Asia-Pacific. Nevertheless, the market is projected to reach $405.5m in value in 2023, growing at a compound annual growth rate of 12.4%. 

Key Questions Answered -

Asia-Pacific uveitis market will be valued at $405.5m in 2023, growing from $179m in 2016, at a compound annual growth rate of 12.4%.
What are the key factors driving the Asia-Pacific uveitis treatment market? 

Corticosteroid therapies dominate the uveitis market, but unmet needs exist in terms of safety and efficacy. 
What are the common targets and mechanisms of action of pipeline therapies? 

Various drivers and barriers will influence the market over the forecast period.
What are the barriers that will limit the uptake of premium-priced therapies in the assessed countries?